Lipocine Completes Phase 3 Trial for Postpartum Depression Drug, Reports Strong Cash Position
LPCN has more than doubled off its 52-week low of $2.52.
Summary
Lipocine Inc. announced the completion of the Last Patient Last Visit in its pivotal Phase 3 trial for LPCN 1154 in postpartum depression and reported a strong cash position of approximately $19 million.
Key Events · Product Development and Regulatory · LPCN
-
Phase 3 Trial Completion
The company announced the Last Patient Last Visit (LPLV) has been completed in its pivotal Phase 3 clinical trial evaluating LPCN 1154 for postpartum depression (PPD). This milestone signifies the end of the active treatment and observation phase for all enrolled patients.
-
Strong Cash Position
Lipocine reported approximately $19 million in cash and cash equivalents as of January 31, 2026. This preliminary, unaudited estimate indicates a solid financial runway for the company.
Analysis · LPCN · Life Sciences
The completion of the Last Patient Last Visit (LPLV) in the pivotal Phase 3 trial for LPCN 1154 marks a significant de-risking milestone for Lipocine's lead candidate for postpartum depression. This indicates the trial's active phase is complete, moving the company closer to data analysis and a potential 505(b)(2) NDA submission in 2026. The reported positive safety profile and high study drug compliance during the trial are encouraging. Concurrently, the company's preliminary cash and cash equivalents of approximately $19 million as of January 31, 2026, provides a robust financial runway, especially for a company of its size, supporting ongoing development efforts and future commercialization plans. This combination of clinical progress and financial stability positions Lipocine favorably as it approaches key data readouts.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LPCN was trading at $9.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.1M. The 52-week trading range was $2.52 to $12.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.